Nlrx1 ligands
AssigneeLandos Biopharma, Inc.
InventorsJosep Bassaganya-Riera, Andrew Leber, Nuria Tubau-Juni, Raquel Hontecillas
Life of this patent
Estimating the term…
Abstract
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat conditions such as autoimmune diseases, allergic diseases, chronic and/or inflammatory central nervous system diseases, chronic and/or inflammatory respiratory diseases, cancer, and infectious diseases. Exemplary conditions include multiple sclerosis, asthma, Alzheimer's disease, Parkinson's disease, neuroinflammation resulting from, for example, stroke, traumatic brain injury, or spinal cord injury, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and inflammatory bowel disease.
Claims30
A compound of Formula (I) having an A ring, a B ring, a C ring, a D ring, and an E ring:
- or a salt or ester thereof, wherein:
- A1 and A5 are each independently O, N(RA), N(RALK), C(RA)2, C(RA), or N;
- A2, A3, and A4 are each independently O, N(RA), N(RALK), C(RA)2, C(RA), N, C(RA)(RO), C(RO), or C(═O), with the proviso that A4 is optionally absent;
- A6 and A7 are each independently C(RA) or N;
- A8, A9, and A10 are each independently O, N(RA), N(RALK), C(RA)2, C(RA), or N;
- A11, A12, A13, A14, and A15 are each independently O, N(RA), N(RALK), C(RA)2, C(RA), N, C(RA)(RO), C(RO), or C(═O), with the proviso that A14 is optionally absent;
- each - - - between adjacent atoms represents a bond that is present or absent;
- L is O, N(RL), or C(RL)2;
- RO in each instance is independently hydroxyl or optionally substituted alkyloxy;
- RALK in each instance is independently C1-C6 alkyl;
- RA, RB, and RL in each instance is independently, hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxyl, carboxyl, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy, or an optionally substituted non-aromatic heterocyclic group.
Dependencies are inferred from the claim text.